Journal article
The role of radiotherapy in the management of patients with diffuse low grade glioma A systematic review and evidence-based clinical practice guideline
Journal of neuro-oncology, Vol.125(3), pp.551-583
12/01/2015
DOI: 10.1007/s11060-015-1948-1
PMID: 26530266
Abstract
Questions
What is the optimal role of external beam radiotherapy in the management of adult patients with newly diagnosed low-grade glioma (LGG) in terms of improving outcome (i.e. survival, complications, seizure control or other reported outcomes of interest)?
Which radiation strategies (dose, timing, fractionation, stereotactic radiation, brachytherapy, chemotherapy) improve outcomes compared to standard external beam radiation therapy in the initial management of low grade gliomas in adults?
Do specific factors (e.g. age, volume, extent of resection, genetic subtype) identify subgroups with better outcomes following radiation therapy than the general population of adults with newly diagnosed low-grade gliomas?
These recommendations apply to adults with newly diagnosed diffuse LGG.
Level I Radiotherapy is recommended in the management of newly diagnosed low-grade glioma in adults to prolong progression free survival, irrespective of extent of resection.
Level II Radiotherapy is recommended in the management of newly diagnosed low grade glioma in adults as an equivalent alternative to observation in preserving cognitive function, irrespective of extent of resection.
Level III Radiotherapy is recommended in the management of newly diagnosed low grade glioma in adults to improve seizure control in patients with epilepsy and subtotal resection.
Level III Radiotherapy is recommended in the management of newly diagnosed low-grade glioma in adults to prolong overall survival in patients with subtotal resection.
Level III Consideration of the risk of radiation induced morbidity, including cognitive decline, imaging abnormalities, metabolic dysfunction and malignant transformation, is recommended when the delivery of radiotherapy is selected in the management of newly diagnosed low-grade glioma in adults.
Level I Lower dose radiotherapy is recommended as an equivalent alternative to higher dose immediate postoperative radiotherapy (45-50.4 vs. 59.4-64.8 Gy) in the management of newly diagnosed low-grade glioma in adults with reduced toxicity.
Level III Delaying radiotherapy until recurrence or progression is recommended as an equivalent alternative to immediate postoperative radiotherapy in the management of newly diagnosed low-grade glioma in adults but may result in shorter time to progression.
Level III The addition of chemotherapy to radiotherapy is not recommended over whole brain radiotherapy alone in the management of low-grade glioma, as it provides no additional survival benefit.
Level III Limited-field radiotherapy is recommended over whole brain radiotherapy in the management of low-grade glioma.
Level III Either stereotactic radiosurgery or brachytherapy are recommended as acceptable alternatives to external radiotherapy in selected patients.
Level II It is recommended that age greater than 40 years, astrocytic pathology, diameter greater than 6 cm, tumor crossing the midline and preoperative neurological deficit be considered as negative prognostic indicators when predicting overall survival in adult low grade glioma patients treated with radiotherapy.
Level II It is recommended that smaller tumor size, extent of surgical resection and higher mini-mental status exam be considered as positive prognostic indicators when predicting overall survival and progression free survival in patients in adult low grade glioma patients treated with radiotherapy.
Level III It is recommended that seizures at presentation, presence of oligodendroglial histological component and 1p19q deletion (along with additional relevant factors-see Table 1) be considered as positive prognostic indicators when predicting response to radiotherapy in adults with low grade gliomas.
Level III It is recommended that increasing age, decreasing performance status, decreasing cognition, presence of astrocytic histological component (along with additional relevant factors (see Tables 1, 2) be considered as negative prognostic indicators when predicting response to radiotherapy.
Details
- Title: Subtitle
- The role of radiotherapy in the management of patients with diffuse low grade glioma A systematic review and evidence-based clinical practice guideline
- Creators
- Timothy C. Ryken - Univ Kansas, Med Ctr, Dept Neurosurg, Kansas City, KS 66103 USAIan Parney - Mayo Clin, Dept Neurosurg, Rochester, MN USAJohn Buatti - Univ Iowa Hosp & Clin, Dept Radiat Oncol, Iowa City, IA 52242 USASteven N. Kalkanis - Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI USAJeffrey J. Olson - Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA
- Resource Type
- Journal article
- Publication Details
- Journal of neuro-oncology, Vol.125(3), pp.551-583
- Publisher
- Springer Nature
- DOI
- 10.1007/s11060-015-1948-1
- PMID
- 26530266
- ISSN
- 0167-594X
- eISSN
- 1573-7373
- Number of pages
- 33
- Grant note
- Millennium; Takeda Pharmaceutical Company Ltd National Cancer Institute; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) Genentech; Roche Holding
- Language
- English
- Date published
- 12/01/2015
- Academic Unit
- Radiation Oncology; Neurosurgery; Otolaryngology
- Record Identifier
- 9984303896302771
Metrics
4 Record Views